Abstracts tagged "Lupus nephritis"

Abstract Number: 0035 • ACR Convergence 2020
Distinct Biological Pathways in Both Blood and Kidney Further Define Molecular Profiles Across Diverse Nephritides
Loqmane Seridi¹, Matteo Cesaroni¹, Qingxuan Song², Ashley Orillion¹, Frédéric Baribaud¹, Tatiana Ort¹, Sheng Gao², Tomas Parker³, James Chevalier³, Dan Levine³, Alan Perlman³ and Jarrat Jordan¹, ¹Janssen Research & Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, ³The Rogosin Institute, New York Presbyterian Hospital-Weill Medical College of Cornell University New York, NY, USA., New York, NY
Background/Purpose: Approximately 40% of SLE patients will develop Lupus Nephritis (LN), of which 10-30 % will progress to end-stage renal disease. To further understand LN…
Abstract Number: 0855 • ACR Convergence 2020
Treatment of SLE with or Without Nephritis with the Immunoproteasome Inhibitor KZR-616: Updated Results of the MISSION Study
Richard Furie¹, Samir Parikh², Kenneth Harvey³, Christopher Kirk⁴, Darrin Bomba⁴ and MK Farmer⁵, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²The Ohio State University, Columbus, OH, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Inc, San Francisco, CA, ⁵Kezar, Raleigh, NC
Background/Purpose: Immunoproteasome inhibition has demonstrated meaningful therapeutic potential in preclinical models of systemic lupus erythematosus (SLE) and lupus nephritis (LN). KZR-616 is a first-in-class selective…
Abstract Number: 1513 • ACR Convergence 2020
Role of Platelet C4d in Thrombosis and Lupus Nephritis
Michelle Petri¹, Jessica Li², John Conklin³, Tyler O'Malley⁴, Jo-Anne Ligayon⁵, Leilani Wolover⁵ and Thierry Dervieux⁶, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD, ³Exagen Inc., Vista, CA, ⁴Exagen, Inc, San Diego, CA, ⁵Exagen Diagnostics, San Diego, CA, ⁶Prometheus Biosciences, Inc. (former employee of Exagen Diagnostics), Irvine, CA
Background/Purpose: The SLE thrombosis risk equation contains three components: lupus anticoagulant (dRVVT), low C3 and C4d bound to platelets (platelet C4d). We examined the role…
Abstract Number: 1814 • ACR Convergence 2020
The Association of Urinary Membrane Attack Complex (C5b-9) with Proteinuria and Glomerular Activity in Lupus Nephritis
Shudan Wang¹, Erica Moore², Brianna Lally³, Beatrice Goilav⁴, Chaim Putterman³ and Anna Broder⁵, ¹Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, ³Albert Einstein College of Medicine, Bronx, NY, ⁴The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁵Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Complement activation is known to play a major role in lupus nephritis (LN). Urinary membrane attack complex (C5b-9) has been shown to correlate with…
Abstract Number: 0242 • ACR Convergence 2020
Autoantibody Profile and Ethnicity: Risk Factors for Accelerated Development of Lupus Nephritis
Majed Albirdisi¹, David d'Cruz², Shirish Sangle² and Natasha Jordan³, ¹King Fahad Medical City, riyadh, Saudi Arabia, ²guys and st thomas hospital, london, United Kingdom, ³addebrooke's hospital, cambridge, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease. African ancestry is associated with an increased risk of Lupus Nephritis (LN). Anti-DNA autoantibodies play…
Abstract Number: 0859 • ACR Convergence 2020
Biomarkers of B-cell Depletion and Response in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis
Ed Vital¹, Philippe Remy², Luis Fernando Quintana Porras³, Laurent Chiche⁴, Dominique Chauveau⁵, Richard Furie⁶, Thomas Schindler⁷, Jay Garg⁸, Matthew Cascino⁸, Zahir Amoura⁹, Andrea Doria¹⁰, Cary Looney⁸ and Dario Roccatello¹¹, ¹University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²APHP Groupe Hospitalier Henri-Mondor, Creteil, France, ³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ⁴Hôpital Européen, Marseille, France, ⁵Hôpital Rangueil, Centre Hospitalier Univ de Toulouse, Toulouse, France, ⁶Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁷F. Hoffmann-La Roche Ltd., Basel, Switzerland, ⁸Genentech, Inc., South San Francisco, CA, ⁹Hôpital Pitié-Salpêtrière, Paris, ¹⁰University of Padua, Padua, Italy, ¹¹S Giovanni Hospital, Univ of Turin, Turin, Italy
Background/Purpose: Incomplete B-cell and plasmablast depletion, as measured using highly sensitive flow cytometry (HSFC), is associated with lower response rates following rituximab in SLE [1].…
Abstract Number: 1514 • ACR Convergence 2020
The Impact of Renal Transplantation on Cardiovascular Events Among Patients with End-State Kidney Disease Due to Lupus Nephritis: A Nationwide Cohort Study
April Jorge¹, Xiaoqing Fu², Yuqing Zhang³, Hyon Choi⁴ and Zachary Wallace⁵, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Harvard Medical School, Boston, ⁴Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, ⁵Harvard Medical School, Boston
Background/Purpose:A major complication of systemic lupus erythematosus (SLE) is the progression of lupus nephritis (LN) to end-stage kidney disease (ESKD). Both SLE and ESKD are…
Abstract Number: 1815 • ACR Convergence 2020
Dynamic Changes in Microbiota Representation of a Gut Pathobiont and Clinical Disease Activity in Patients with Lupus Nephritis
Doua Azzouz¹, Ze Chen², Zhi Li³, Peter Izmirly⁴, Jing Deng¹, David Fenyo³, Jill Buyon¹, Alexander Alekseyenko⁵ and Gregg Silverman⁶, ¹Department of Medicine, NYU School of Medicine, New York, NY, ²Department of Microbiology, NYU School of Medicine, New York, NY, ³Institute for Systems Genetics, NYU School of Medicine, New York, NY, ⁴Department of Medicine, New York University School of Medicine, New York, NY, ⁵Medical University of South Carolina, Charleston, SC, ⁶Laboratory of B cell immunobiology, Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: From a cross-sectional cohort, we have recently identified a candidate human gut pathobiont, Ruminococcus gnavus (RG) of the Lachnospiraceae family and Blautia genus that…
Abstract Number: 0243 • ACR Convergence 2020
The Role of Anti-dsDNA Antibodies in Predicting Incident Lupus Nephritis in Newly Diagnosed Lupus
Pooja Kumari¹, Viswanathan Ramakrishnan², Jihad Obeid², Diane Kamen³ and Jim Oates⁴, ¹The university of Tennesse Health Science center, Memphis, TN, ²medical university of south carolina, south carolina, ³Medical University of South Carolina, Charleston, SC, ⁴Medical University of South Carolina, Charleston, SC, Charleston, SC
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that leads to significant morbidity and mortality. Therefore, it is essential to…
Abstract Number: 0862 • ACR Convergence 2020
Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE
Teun van Gelder¹, Robert Huizinga², Neil Solomons² and Laura Lisk³, ¹Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, ²Aurinia Pharmaceuticals, Victoria, BC, Canada, ³Aurinia Pharmaceuticals Inc., Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor, structurally similar to cyclosporine A (CsA). In a Phase 3 clinical trial in patients with active lupus…
Abstract Number: 1515 • ACR Convergence 2020
Renal Responder Status and Associated Clinical Variables in the Lupus Accelerating Medicines Partnership Cohort
Philip Carlucci¹, Andrea Fava², Kristina Deonaraine¹, Jessica Li³, David Wofsy⁴, Judith James⁵, Chaim Putterman⁶, Betty Diamond⁷, Derek Fine⁸, Jose Monroy-Trujillo⁸, Kristin Haag⁸, William Apruzzese⁹, H. Michael Belmont¹⁰, Peter Izmirly¹¹, Sean Connery¹², Fernanda Payan-Schober¹², Richard Furie¹³, Celine Berthier¹⁴, Maria Dall'Era¹⁵, Kerry Cho¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, The Accelerating Medicines Partnership in SLE Network¹⁹, Michelle Petri²⁰ and Jill Buyon²¹, ¹New York University School of Medicine, New York, ²Johns Hopkins, Baltimore, ³Johns Hopkins University, Baltimore, MD, ⁴University of California San Francisco, San Francisco, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷Northwell Health, Hartford, ⁸Johns Hopkins University, Baltimore, ⁹., Boston, ¹⁰NYU School of Medicine, New York, NY, ¹¹Department of Medicine, New York University School of Medicine, New York, NY, ¹²Texas Tech University Health Sciences Center, Lubbock, ¹³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ¹⁴University of Michigan, Ann Arbor, ¹⁵Division of Rheumatology, University of California, San Francisco, CA, ¹⁶University of California San Francisco, San Francisco, ¹⁷Medical University of South Carolina, Charleston, SC, ¹⁸School of Health Sciences, University of California, La Jolla, ¹⁹Multiple Institutions, Multiple Cities, ²⁰Johns Hopkins University School of Medicine, Baltimore, ²¹Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Poor therapeutic response rates contribute to the increased morbidity and mortality associated with lupus nephritis. Early identification of patients likely to respond is crucial…
Abstract Number: 1816 • ACR Convergence 2020
Urine Biomarkers of Tubulointersitital Damage in Lupus Nephritis
Brianna Lally¹, Shudan Wang², Sammy Chalmers³, Wenzhu Mowrey³, Tamar Rubinstein⁴, Beatrice Goilav⁵ and Anna Broder⁶, ¹Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, New York, NY, ³Albert Einstein College of Medicine, Bronx, ⁴Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY, ⁵The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁶Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Tubulointerstitial disease (TID), defined as tubulointerstitial inflammation (TII) or interstitial fibrosis/tubular atrophy (IFTA), is associated with progression to end stage renal disease (ESRD) in…
Abstract Number: 0250 • ACR Convergence 2020
Lupus Nephritis and Renal Outcomes in African-Americans: The Accelerating Medicines Partnership Cohort Experience
Andrea Fava¹, Jessica Li¹, Philip Carlucci², David Wofsy³, Judith James⁴, Chaim Putterman⁵, Betty Diamond⁶, Derek Fine⁷, Jose Monroy-Trujillo⁷, Kristin Haag⁷, Kristina Deonaraine⁸, The Accelerating Medicines Partnership in SLE Network⁹, William Apruzzese¹⁰, Jill Buyon¹¹ and Michelle Petri¹², ¹Johns Hopkins University, Baltimore, MD, ²New York University School of Medicine, New York, NY, ³University of California San Francisco, San Francisco, CA, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK, ⁵Albert Einstein College of Medicine, Bronx, NY, ⁶Northwell Health, Manhasset, NY, ⁷Johns Hopkins University, Baltimore, ⁸New York University School of Medicine, New York, ⁹Multiple Institutions, Multiple Cities, ¹⁰., Boston, ¹¹Department of Medicine, NYU School of Medicine, New York, NY, ¹²Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: The Accelerating Medicines Partnership (AMP) will use multi-omics modalities including single cell RNA sequencing to understand lupus nephritis with the ultimate goal to devise…
Abstract Number: 0867 • ACR Convergence 2020
Hydroxychloroquine Use Predicts Significantly Higher Patient and Graft Survival in Post-Renal Transplant Lupus Nephritis Patients
Shivani Garg¹, Tripti Singh¹, Sarah Panzer² and Christie Bartels³, ¹UW Madison, Madison, WI, ²UW-Madison, Madison, ³University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is a pivotal therapy for lupus nephritis (LN) as it contributes to 65% lower mortality and 84% lower renal damage compared to…
Abstract Number: 1516 • ACR Convergence 2020
The Value of Renal Biopsy at Lower Levels of Proteinuria in Patients Enrolled in the Lupus Accelerating Medicines Partnership
Philip Carlucci¹, Kristina Deonaraine¹, Andrea Fava², Jessica Li³, David Wofsy⁴, Judith James⁵, Chaim Putterman⁶, Betty Diamond⁷, Derek Fine⁸, Jose Monroy-Trujillo⁸, Kristin Haag⁸, William Apruzzese⁹, H. Michael Belmont¹⁰, Peter Izmirly¹¹, Sean Connery¹², Fernanda Payan-Schober¹², Richard Furie¹³, Celine Berthier¹⁴, Maria Dall'Era¹⁵, Kerry Cho¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, The Accelerating Medicines Partnership in SLE Network¹⁹, Michelle Petri²⁰ and Jill Buyon²¹, ¹New York University School of Medicine, New York, ²Johns Hopkins, Baltimore, ³Johns Hopkins University, Baltimore, MD, ⁴University of California San Francisco, San Francisco, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷Northwell Health, Hartford, ⁸Johns Hopkins University, Baltimore, ⁹., Boston, ¹⁰NYU School of Medicine, New York, NY, ¹¹Department of Medicine, New York University School of Medicine, New York, NY, ¹²Texas Tech University Health Sciences Center, Lubbock, ¹³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ¹⁴University of Michigan, Ann Arbor, ¹⁵Division of Rheumatology, University of California, San Francisco, CA, ¹⁶University of California San Francisco, San Francisco, ¹⁷Medical University of South Carolina, Charleston, SC, ¹⁸School of Health Sciences, University of California, La Jolla, ¹⁹Multiple Institutions, Multiple Cities, ²⁰Johns Hopkins University School of Medicine, Baltimore, ²¹Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Lupus nephritis continues to be the complication with the highest standardized mortality ratio in Systemic Lupus Erythematosus (SLE), and a late diagnosis associates with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].